What is the most recent earnings date for ENTA stock?
ENANTA PHARMACEUTICALS INC (ENTA) last reported earnings on 2/9/2026.
ENANTA PHARMACEUTICALS INC (ENTA) Earnings History & Surprises
NASDAQ:ENTA • US29251M1062
Current stock price
12.7 USD
-0.71 (-5.29%)
At close:
12.7778 USD
+0.08 (+0.61%)
After Hours:
ENTA Earnings overview
Past quarterly earnings results for ENANTA PHARMACEUTICALS INC (ENTA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q2 / 2026
- EPS Estimate
- -$0.54
- Revenue Estimate
- 17.026M
Last Reported
Most Recent- Release Date
- Feb 9, 2026
- Period
- Q1 / 2026
- EPS Reported
- -$0.42
- EPS Surprise
- 49.01%
- Revenue Surprise
- 13.07%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | -0.42 | -0.82 | 49.01% | 60.00% | 18.615M | 16.463M | 13.07% | 9.76% |
| Q4 2025 | -0.87 | -1.04 | 16.46% | 36.03% | 15.125M | 16.275M | -7.07% | 3.55% |
| Q3 2025 | -0.85 | -1.30 | 34.72% | 20.56% | 18.314M | 15.85M | 15.55% | 1.91% |
| Q2 2025 | -1.06 | -1.16 | 8.52% | 27.89% | 14.926M | 16.271M | -8.27% | -12.48% |
| Q1 2025 | -1.05 | -1.38 | 23.90% | 33.54% | 16.959M | 17.594M | -3.61% | -5.80% |
| Q4 2024 | -1.36 | -1.18 | -14.94% | -2.26% | 14.607M | 18.291M | -20.14% | -22.84% |
| Q3 2024 | -1.07 | -1.48 | 27.64% | 42.47% | 17.971M | 17.522M | 2.56% | -4.88% |
| Q2 2024 | -1.47 | -1.32 | -11.01% | 17.88% | 17.054M | 16.416M | 3.89% | -4.16% |
| Q1 2024 | -1.58 | -1.22 | -29.73% | -13.67% | 18.003M | 21.708M | -17.07% | -23.68% |
| Q4 2023 | -1.33 | -2.19 | 39.26% | -4.72% | 18.932M | 17.848M | 6.07% | -6.83% |
| Q3 2023 | -1.86 | -2.38 | 21.99% | -21.57% | 18.892M | 18.419M | 2.57% | -3.02% |
| Q2 2023 | -1.79 | -2.02 | 11.37% | -9.82% | 17.795M | 19.566M | -9.05% | -4.94% |
| Q1 2023 | -1.39 | -1.63 | 14.56% | 6.08% | 23.59M | 23.02M | 2.48% | -14.68% |
| Q4 2022 | -1.27 | -1.38 | 7.94% | -4.10% | 20.32M | 23.319M | -12.86% | -13.83% |
| Q3 2022 | -1.53 | -1.41 | -8.21% | -28.57% | 19.48M | 21.114M | -7.74% | -9.90% |
| Q2 2022 | -1.63 | -1.45 | -12.10% | -49.54% | 18.72M | 21.084M | -11.21% | -7.00% |
| Q1 2022 | -1.48 | -1.10 | -34.19% | -260.98% | 27.65M | 27.906M | -0.92% | -12.89% |
| Q4 2021 | -1.22 | -1.25 | 2.14% | 16.44% | 23.58M | 26.869M | -12.24% | -0.21% |
| Q3 2021 | -1.19 | -1.30 | 8.77% | -67.61% | 21.62M | 22.298M | -3.04% | 15.92% |
| Q2 2021 | -1.09 | -1.00 | -8.82% | -263.33% | 20.13M | 24.864M | -19.04% | -27.12% |
| Q1 2021 | -0.41 | -0.75 | 45.68% | -163.08% | 31.74M | 29.367M | 8.08% | -39.62% |
| Q4 2020 | -1.46 | -0.97 | -49.99% | - | 23.63M | 26.26M | -10.02% | - |
| Q3 2020 | -0.71 | -0.86 | 17.62% | - | 18.65M | 26.843M | -30.52% | - |
| Q2 2020 | -0.30 | -0.91 | 67.04% | - | 27.62M | 27.856M | -0.85% | - |
| Q1 2020 | 0.65 | 0.56 | 16.71% | - | 52.57M | 59.231M | -11.25% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
27.18%
Max EPS beat (4)
49.01%
Min EPS beat (4)
8.52%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
3.32%
Max Revenue beat (4)
15.55%
Min Revenue beat (4)
-8.27%
Analysis
In the last 4 quarters, ENTA has consistently beaten EPS estimates in all releases
ENTA has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, ENTA has beaten the EPS estimates by 27.2% on average.
In the last 4 quarters, ENTA has beaten the revenue estimates by 3.3% on average.
Related analysis
ENANTA PHARMACEUTICALS INC / ENTA Earnings FAQ
Can you provide information on whether ENANTA PHARMACEUTICALS INC beat earnings estimates in the last quarter?
ENANTA PHARMACEUTICALS INC (ENTA) beat EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often ENANTA PHARMACEUTICALS INC beats earnings estimates?
In the last 4 quarters, ENANTA PHARMACEUTICALS INC (ENTA) has beaten EPS estimates in 4 out of 4 releases.